PharmTech Drug Digest 11.20
|Articles|December 1, 2011

Pharmaceutical Technology Europe

  • Pharmaceutical Technology Europe-12-01-2011
  • Volume 23
  • Issue 12

Contract API Manufacturing: The Year in Review

Expansion activity was limited as fine-chemical producers and CMOs of API and intermediates grapple with changing industry fundamentals.

By Patricia van Arnum

The year 2011 was another year of transition for fine-chemical producers and contract manufacturers of APIs and intermediates. As the pharmaceutical industry as a whole deals with slowing growth, increased generic-drug incursion, reduced R&D productivity, and the financing pinch for smaller and emerging bio/pharmaceutical companies, so do its suppliers. Expansion activity among fine-chemical producers and contract API manufacturers was limited although certain areas, such as high-potency manufacturing, continue to attract investment as do biopharmaceutical manufacturing and related services.

This article was also published in our US sister publication Pharmaceutical Technology and can be read here.

Articles in this issue

almost 15 years ago

Mitigating Personnel Risks

almost 15 years ago

The Impact Of Single-Use Systems

almost 15 years ago

Contamination: Invisible And Airborne

almost 15 years ago

Choosing Cleanroom Clothing

almost 15 years ago

The Employment Outlook Brightens

almost 15 years ago

It’s déjà vu all over again

almost 15 years ago

News

almost 15 years ago

Impact of Ageing

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.